Impact of body composition on outcomes of immune checkpoint inhibitor combination therapy in patients with previously untreated advanced renal cell carcinoma

CONCLUSION: The SFI can be potentially utilized as an effective predictive and prognostic biomarker for first-line ICI combination therapy for advanced RCC.PMID:38653590 | DOI:10.1016/j.urolonc.2024.04.008

Source: Urologic Oncology - April 23, 2024 Category: Urology & Nephrology Authors: Hiroki Ishihara Koichi Nishimura Takashi Ikeda Hironori Fukuda Kazuhiko Yoshida Junpei Iizuka Tsunenori Kondo Toshio Takagi Source Type: research